No price com­pe­ti­tion in PD-(L)1? That might not last long as EQRx, CStone read out late-stage win for chal­lenger

Drug pric­ing dis­rup­tor EQRx has made a show about its mis­sion to ag­gres­sive­ly dis­count drug mar­kets dom­i­nat­ed by ex­pen­sive med­i­cines with no mean­ing­ful price com­pe­ti­tion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER